PLAT and myocardial infarction: Furthermore, a phase II trial of rhTNK-tpa demonstrated a significant increase in myocardial infarction thrombolysis (TIMI) levels 2–3 compared to rt-PA, underscoring the enhanced efficacy of rhTNK as a third-generation thrombolytic agent [22].